Feeling full after small meals, experiencing nausea or noticing food seems to "sit" in your stomach for hours — these are recognisable experiences for many people starting Wegovy, Ozempic or Mounjaro. For most, they are temporary and manageable. But for some, especially those with certain risk factors, these symptoms can signal a more significant problem: delayed gastric emptying, also known as gastroparesis.

Understanding the connection between GLP-1 medications and stomach emptying helps you recognise early warning signs and have informed conversations with your doctor.

What is gastroparesis?

Gastroparesis literally means "stomach paralysis" — a condition in which the stomach takes abnormally long to empty its contents into the small intestine. Normally, the muscles of the stomach wall contract in waves to push food through. When the nerves controlling these muscles are damaged or not working properly, this process slows dramatically.

Symptoms of gastroparesis include:

People with type 2 diabetes are at significantly higher risk because high blood glucose over time damages the vagus nerve, which controls stomach muscle contractions. It is estimated that up to 50% of people with long-standing type 2 diabetes have some degree of delayed gastric emptying — often without realising it.

How do GLP-1 medications slow the stomach?

Slowing gastric emptying is actually one of the intended mechanisms of GLP-1 receptor agonists. When GLP-1 receptors in the gut and brain are activated by semaglutide or tirzepatide, several things happen: appetite decreases, the pancreas releases more insulin in response to food, and stomach emptying slows.

This delayed emptying is beneficial in several ways: food enters the small intestine more gradually, which reduces post-meal blood sugar spikes. It also means the feeling of fullness lasts longer, which helps with reduced calorie intake and weight loss.

For most people, the slowing is modest and well-tolerated. The mild nausea many people experience in the first weeks of treatment is partly a result of this slowing — and typically fades as the body adjusts.

When does it become a problem?

Problems arise when gastric emptying slows too much. In a large study published in JAMA in 2023 (Sodhi et al.), people using semaglutide for weight loss had a significantly higher risk of developing gastroparesis, ileus (intestinal blockage) and pancreatitis compared to those using a different weight-loss medication. The absolute risk remained low, but the relative increase was notable — reinforcing the importance of awareness.

People with pre-existing gastroparesis are at particular risk. If the stomach already empties slowly before starting treatment, adding a medication that slows it further can significantly worsen symptoms.

What are the warning signs to watch for?

While some nausea in the first weeks of GLP-1 treatment is expected, the following symptoms warrant a conversation with your doctor:

If symptoms are severe — such as inability to keep fluids down or severe abdominal pain — seek medical attention promptly rather than waiting for a routine appointment.

Who is at higher risk?

Not everyone faces the same risk. Those more likely to experience significant slowing of gastric emptying include:

If you have any of these risk factors, it is worth discussing gastric emptying proactively with your doctor before or shortly after starting treatment.

What has the FDA said?

In 2023, the FDA issued a Drug Safety Communication highlighting the risk of pulmonary aspiration (inhaling stomach contents into the lungs) during procedures requiring anaesthesia or sedation in patients taking GLP-1 receptor agonists. Because these medications slow gastric emptying, food or liquid can remain in the stomach for much longer than usual — even after the recommended pre-procedure fasting period.

The FDA advised that patients and healthcare providers discuss GLP-1 medication use ahead of any planned surgical or diagnostic procedure. Some anaesthesiology societies now recommend holding GLP-1 medications before elective procedures — the exact duration depends on which medication and the patient's circumstances.

Important: always tell your surgical team, dentist and any other healthcare provider that you are taking a GLP-1 medication before any procedure involving sedation or anaesthesia.

What should you do if you experience symptoms?

If you develop significant symptoms, here is what to consider — always in consultation with your doctor:

Is gastroparesis caused by GLP-1 medication permanent?

In most cases, delayed gastric emptying that occurs or worsens during GLP-1 treatment improves when the dose is reduced or the medication is stopped. The medications do not appear to cause permanent structural changes to the stomach nerves in the way that long-standing diabetes can.

However, if you had pre-existing gastroparesis before starting treatment, that underlying condition remains — the medication was aggravating it rather than causing it. In that case, treating the gastroparesis itself (often with dietary changes, prokinetic medications or other approaches) becomes important.

Conclusion

Delayed gastric emptying is a real consideration for anyone taking GLP-1 medications. For the vast majority of people, the mild stomach slowing these medications produce is part of how they work and causes only temporary, manageable symptoms. But if you notice persistent vomiting, severe bloating, inability to eat or drink, or worsening blood sugar control, these symptoms deserve medical attention.

Being aware of the risk, knowing who is at higher risk, and understanding the FDA's advisory about procedures are all part of using these medications safely. As always, your doctor is the best person to help you navigate any concerns about your treatment.

This article is for informational purposes only and does not replace individual medical advice. Always speak to your doctor about your treatment.

Sources